Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis.

Dermatol Ther (Heidelb)

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Published: October 2021

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484402	PMC
http://dx.doi.org/10.1007/s13555-021-00615-8	DOI Listing

Publication Analysis

correction efficacy

efficacy safety

safety trends

trends continuous

continuous long-term

long-term crisaborole

crisaborole patients

patients aged ≥ 2

aged ≥ 2 years

years mild-to-moderate

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!